Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection

James Greenwood, Carsten Schwarz, Urte Sommerwerck, Edward F Nash, Michael Tamm, Weihua Cao, Paul Mastoridis, Laurie Debonnett, Kamal Hamed, James Greenwood, Carsten Schwarz, Urte Sommerwerck, Edward F Nash, Michael Tamm, Weihua Cao, Paul Mastoridis, Laurie Debonnett, Kamal Hamed

Abstract

Background: This study assessed the ease of use of tobramycin inhalation powder (TIP) administered via T-326 inhaler versus tobramycin inhalation solution (TIS) and colistimethate sodium (COLI), both administered via nebulizers, for the treatment of chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF).

Methods: A real-world, open-label, crossover, interventional phase IV study was conducted in CF patients aged ⩾6 years with forced expiratory volume in 1 second (FEV1) ⩾25% to ⩽90% predicted. Patients were assigned to one of the three treatment arms in Cycle 1; all patients received TIP in Cycle 2. Each cycle consisted of 28 days on and 28 days off the treatment.

Results: A total of 60 patients [mean (standard deviation) age, 27.6 (8.4) years] were allocated to three treatment arms [TIS/TIP ( n = 14); COLI/TIP ( n = 28); TIP/TIP ( n = 18)] in Cycle 1. The mean total administration time, which included device setup and cleaning, in Cycle 1 versus Cycle 2 for TIS/TIP, COLI/TIP, and TIP/TIP arms were 37.0 versus 5.0 min, 16.4 versus 3.8 min, and 4.2 versus 3.4 min, respectively. The difference in mean total administration time was significantly shorter in Cycle 2 than in Cycle 1 for TIS/TIP ( p = 0.0112) and COLI/TIP ( p = 0.0016) arms. Overall, 12 patients were found to have contaminated devices across the two treatment cycles. In the TIP/TIP arm, no contamination of the T-326 inhaler was observed in either cycle. Treatment satisfaction, assessed by the Treatment Satisfaction Questionnaire for Medication and ACCEPT® questionnaire, was better overall for TIP compared with TIS and COLI. There were no unexpected adverse events and most were mild or moderate in intensity.

Conclusion: The T-326 inhaler used to deliver TIP was easy to use, required shorter total administration time, and was much less frequently contaminated than the nebulizers. The safety findings observed for TIP were generally consistent with its established safety profile.

Trial registration: ClinicalTrials.gov NCT01844778.

Keywords: Pseudomonas aeruginosa; T-326 inhaler; device contamination; ease of use; nebulizer; tobramycin.

Conflict of interest statement

Conflict of interest statement: JG received honorarium for participation in a Novartis-sponsored advisory board and received educational grants to attend conferences from Novartis. CS received financial support from Novartis for an investigator-initiated trial. US, EFN, and MT have nothing to disclose. WC, PM, LD, and KH are full-time employees of Novartis Pharmaceuticals Corporation (East Hanover, NJ, USA).

Figures

Figure 1.
Figure 1.
(a) Study design, (b) Patient disposition. *Patients on continuous COLI were to observe a 24-h COLI-free period before the start of TIP at Visit 4. Note: Patients with COLI could follow a cyclic or noncyclic regimen dependent on local treatment practice. AEs, adverse events; COLI, colistimethate sodium; TIP, tobramycin inhalation powder; TIS, tobramycin inhalation solution.

References

    1. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.
    1. Della Zuana A, Garcia Dde O, Juliani RC, et al. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. J Bras Pneumol 2014; 40: 119–127.
    1. TOBI (tobramycin inhalation solution). Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2015.
    1. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957–969.
    1. Promixin®. Summary of product characteristics. Profile Pharma Limited: Chichester; (WestSussex), 2015.
    1. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011; 10: 54–61.
    1. Briesacher BA, Quittner AL, Saiman L, et al. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011; 11: 5.
    1. Blau H, Mussaffi H, Mei Zahav M, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007; 33: 491–495.
    1. Lester MK, Flume PA, Gray SL, et al. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care 2004; 49: 1504–1508.
    1. TOBI Podhaler (tobramycin inhalation powder). Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2015.
    1. Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin 2013; 29: 947–956.
    1. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46: 230–238.
    1. Lam J, Vaughan S, Parkins MD. Tobramycin Inhalation Powder (TIP): an efficient treatment strategy for the management of chronic pseudomonas aeruginosa infection in cystic fibrosis. Clin Med Insights Circ Respir Pulm Med 2013; 7: 61–77.
    1. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10(Suppl 2): S125–S137.
    1. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
    1. Regnault A, Balp MM, Kulich K, et al. Validation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosis. J Cyst Fibros 2012; 11: 494–501.
    1. Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real-world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692–698.
    1. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8: 91–96.
    1. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 2011; 24: 175–182.
    1. Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe (Sheff) 2015; 11: 110–118.
    1. Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009; 75: 141–144.
    1. Sawicki GS, Heller KS, Demars N, et al. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol 2015; 50: 127–136.
    1. Von Schantz S, Katajavuori N, Antikainen O, et al. Evaluation of dry powder inhalers with a focus on ease of use and user preference in inhaler-naive individuals. Int J Pharm 2016; 509: 50–58.
    1. Konstan MW, Flume PA, Galeva I, et al. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2016; 51: 372–378.
    1. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013; 68: 344–350.
    1. Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007; 42: 307–313.
    1. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다